Successful treatment of bortezomib-refractory multiple myeloma derived from monoclonal gammopathy of undetermined significance with dose-adjusted lenalidomide therapy in a patient with concomitant end-stage renal disease due to diabetic nephropathy requiring haemodialysis
Malignancy is a fatal complication of end-stage renal disease (ESRD) requiring haemodialysis. However, the successful treatment of haematological malignancies has been rarely reported. We describe the case of a 63-year-old man who presented with IgA-type multiple myeloma (MM; Durie–Salmon stage IIIB...
Gespeichert in:
| Veröffentlicht in: | CEN case reports 2014-05, Vol.3 (1), p.24-29 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 29 |
|---|---|
| container_issue | 1 |
| container_start_page | 24 |
| container_title | CEN case reports |
| container_volume | 3 |
| creator | Kawano, Noriaki Yokota-Ikeda, Naoko Minoda, Kunihiro Hashiguchi, Hiroshi Yoshida, Shuro Kuriyama, Takuro Yamashita, Kiyoshi Miyazaki, Yoshimasa Inoue, Sanshiro Shimao, Yoshiya Kodama, Keiko Uezono, Shigehiro Ueda, Akira |
| description | Malignancy is a fatal complication of end-stage renal disease (ESRD) requiring haemodialysis. However, the successful treatment of haematological malignancies has been rarely reported. We describe the case of a 63-year-old man who presented with IgA-type multiple myeloma (MM; Durie–Salmon stage IIIB) derived from monoclonal gammopathy of undetermined significance concomitant with ESRD due to diabetic nephropathy. First, haemodialysis was initiated before chemotherapy, and bortezomib and dexamethasone were found to be ineffective. Subsequently, 8 courses of dose-adjusted lenalidomide therapy were administered according to the degree of haematological and renal functions. The patient remained in partial remission without disease progression for 21 months. Thus, lenalidomide therapy is effective for bortezomib-refractory MM concomitant with ESRD. |
| doi_str_mv | 10.1007/s13730-013-0078-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5413672</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1899408190</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-66e8c5ec58f20ce0f1a83cdb76fc03ca579d16cb1b9331745508c69b4ab66d683</originalsourceid><addsrcrecordid>eNp9Ustu1TAQDQhEq1KJLRvkJZuAnXc2SKjiJVViAaytiT1JfOVHajul4etxuJeqbFiNx3POmfH4ZNlLRt8wStu3gZVtSXPKyjylXX73ODsvWF_kVVX1Tx6cz7LLEA6UJmRFa9o_y86KLsWias8fvfi2CoEhjKsm0SNEgzYSN5LB-Yi_nFFD7nH0IKLzGzGrjmrRSMyG2hkgEr26RUlG7wwxzjqhnQVNJjDGLRDnbRdbrcSI3iiboEFNVo1KgBVIfqo4E-kC5iAPa4iprjEJKJlaSyRxRg_LRpQlQJKe2sf7QxLOioSJkC7QyjxEmJD4nUykCggBiVyTgkspDBiVIBaX2Z_G8nizKq_sRGZA4xJGb0GF59nTEXTAy1O8yH58_PD96nN-_fXTl6v317moahbzpsFO1CjqbiyoQDoy6Eohh7YZBS0F1G0vWSMGNvRlydqqrmknmn6oYGga2XTlRfbuqLusg0Ep0rs8aL54ZcBv3IHi_1asmvnkbnldsbJpiyTw-iTg3c2KIXKjgkCtwaJbA2dd31e0Yz1NUHaECu9CSN9534ZRvpuJH83Ek0X4biZ-lzivHs53z_hrnQQojoCw7FtEzw9u9Wn74T-qvwGLK-Dj</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1899408190</pqid></control><display><type>article</type><title>Successful treatment of bortezomib-refractory multiple myeloma derived from monoclonal gammopathy of undetermined significance with dose-adjusted lenalidomide therapy in a patient with concomitant end-stage renal disease due to diabetic nephropathy requiring haemodialysis</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kawano, Noriaki ; Yokota-Ikeda, Naoko ; Minoda, Kunihiro ; Hashiguchi, Hiroshi ; Yoshida, Shuro ; Kuriyama, Takuro ; Yamashita, Kiyoshi ; Miyazaki, Yoshimasa ; Inoue, Sanshiro ; Shimao, Yoshiya ; Kodama, Keiko ; Uezono, Shigehiro ; Ueda, Akira</creator><creatorcontrib>Kawano, Noriaki ; Yokota-Ikeda, Naoko ; Minoda, Kunihiro ; Hashiguchi, Hiroshi ; Yoshida, Shuro ; Kuriyama, Takuro ; Yamashita, Kiyoshi ; Miyazaki, Yoshimasa ; Inoue, Sanshiro ; Shimao, Yoshiya ; Kodama, Keiko ; Uezono, Shigehiro ; Ueda, Akira</creatorcontrib><description>Malignancy is a fatal complication of end-stage renal disease (ESRD) requiring haemodialysis. However, the successful treatment of haematological malignancies has been rarely reported. We describe the case of a 63-year-old man who presented with IgA-type multiple myeloma (MM; Durie–Salmon stage IIIB) derived from monoclonal gammopathy of undetermined significance concomitant with ESRD due to diabetic nephropathy. First, haemodialysis was initiated before chemotherapy, and bortezomib and dexamethasone were found to be ineffective. Subsequently, 8 courses of dose-adjusted lenalidomide therapy were administered according to the degree of haematological and renal functions. The patient remained in partial remission without disease progression for 21 months. Thus, lenalidomide therapy is effective for bortezomib-refractory MM concomitant with ESRD.</description><identifier>ISSN: 2192-4449</identifier><identifier>EISSN: 2192-4449</identifier><identifier>DOI: 10.1007/s13730-013-0078-x</identifier><identifier>PMID: 28509247</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Case Report ; Medicine ; Medicine & Public Health ; Nephrology ; Urology</subject><ispartof>CEN case reports, 2014-05, Vol.3 (1), p.24-29</ispartof><rights>Japanese Society of Nephrology 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-66e8c5ec58f20ce0f1a83cdb76fc03ca579d16cb1b9331745508c69b4ab66d683</citedby><cites>FETCH-LOGICAL-c451t-66e8c5ec58f20ce0f1a83cdb76fc03ca579d16cb1b9331745508c69b4ab66d683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413672/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413672/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28509247$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kawano, Noriaki</creatorcontrib><creatorcontrib>Yokota-Ikeda, Naoko</creatorcontrib><creatorcontrib>Minoda, Kunihiro</creatorcontrib><creatorcontrib>Hashiguchi, Hiroshi</creatorcontrib><creatorcontrib>Yoshida, Shuro</creatorcontrib><creatorcontrib>Kuriyama, Takuro</creatorcontrib><creatorcontrib>Yamashita, Kiyoshi</creatorcontrib><creatorcontrib>Miyazaki, Yoshimasa</creatorcontrib><creatorcontrib>Inoue, Sanshiro</creatorcontrib><creatorcontrib>Shimao, Yoshiya</creatorcontrib><creatorcontrib>Kodama, Keiko</creatorcontrib><creatorcontrib>Uezono, Shigehiro</creatorcontrib><creatorcontrib>Ueda, Akira</creatorcontrib><title>Successful treatment of bortezomib-refractory multiple myeloma derived from monoclonal gammopathy of undetermined significance with dose-adjusted lenalidomide therapy in a patient with concomitant end-stage renal disease due to diabetic nephropathy requiring haemodialysis</title><title>CEN case reports</title><addtitle>CEN Case Rep</addtitle><addtitle>CEN Case Rep</addtitle><description>Malignancy is a fatal complication of end-stage renal disease (ESRD) requiring haemodialysis. However, the successful treatment of haematological malignancies has been rarely reported. We describe the case of a 63-year-old man who presented with IgA-type multiple myeloma (MM; Durie–Salmon stage IIIB) derived from monoclonal gammopathy of undetermined significance concomitant with ESRD due to diabetic nephropathy. First, haemodialysis was initiated before chemotherapy, and bortezomib and dexamethasone were found to be ineffective. Subsequently, 8 courses of dose-adjusted lenalidomide therapy were administered according to the degree of haematological and renal functions. The patient remained in partial remission without disease progression for 21 months. Thus, lenalidomide therapy is effective for bortezomib-refractory MM concomitant with ESRD.</description><subject>Case Report</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nephrology</subject><subject>Urology</subject><issn>2192-4449</issn><issn>2192-4449</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp9Ustu1TAQDQhEq1KJLRvkJZuAnXc2SKjiJVViAaytiT1JfOVHajul4etxuJeqbFiNx3POmfH4ZNlLRt8wStu3gZVtSXPKyjylXX73ODsvWF_kVVX1Tx6cz7LLEA6UJmRFa9o_y86KLsWias8fvfi2CoEhjKsm0SNEgzYSN5LB-Yi_nFFD7nH0IKLzGzGrjmrRSMyG2hkgEr26RUlG7wwxzjqhnQVNJjDGLRDnbRdbrcSI3iiboEFNVo1KgBVIfqo4E-kC5iAPa4iprjEJKJlaSyRxRg_LRpQlQJKe2sf7QxLOioSJkC7QyjxEmJD4nUykCggBiVyTgkspDBiVIBaX2Z_G8nizKq_sRGZA4xJGb0GF59nTEXTAy1O8yH58_PD96nN-_fXTl6v317moahbzpsFO1CjqbiyoQDoy6Eohh7YZBS0F1G0vWSMGNvRlydqqrmknmn6oYGga2XTlRfbuqLusg0Ep0rs8aL54ZcBv3IHi_1asmvnkbnldsbJpiyTw-iTg3c2KIXKjgkCtwaJbA2dd31e0Yz1NUHaECu9CSN9534ZRvpuJH83Ek0X4biZ-lzivHs53z_hrnQQojoCw7FtEzw9u9Wn74T-qvwGLK-Dj</recordid><startdate>20140501</startdate><enddate>20140501</enddate><creator>Kawano, Noriaki</creator><creator>Yokota-Ikeda, Naoko</creator><creator>Minoda, Kunihiro</creator><creator>Hashiguchi, Hiroshi</creator><creator>Yoshida, Shuro</creator><creator>Kuriyama, Takuro</creator><creator>Yamashita, Kiyoshi</creator><creator>Miyazaki, Yoshimasa</creator><creator>Inoue, Sanshiro</creator><creator>Shimao, Yoshiya</creator><creator>Kodama, Keiko</creator><creator>Uezono, Shigehiro</creator><creator>Ueda, Akira</creator><general>Springer Japan</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140501</creationdate><title>Successful treatment of bortezomib-refractory multiple myeloma derived from monoclonal gammopathy of undetermined significance with dose-adjusted lenalidomide therapy in a patient with concomitant end-stage renal disease due to diabetic nephropathy requiring haemodialysis</title><author>Kawano, Noriaki ; Yokota-Ikeda, Naoko ; Minoda, Kunihiro ; Hashiguchi, Hiroshi ; Yoshida, Shuro ; Kuriyama, Takuro ; Yamashita, Kiyoshi ; Miyazaki, Yoshimasa ; Inoue, Sanshiro ; Shimao, Yoshiya ; Kodama, Keiko ; Uezono, Shigehiro ; Ueda, Akira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-66e8c5ec58f20ce0f1a83cdb76fc03ca579d16cb1b9331745508c69b4ab66d683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Case Report</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nephrology</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kawano, Noriaki</creatorcontrib><creatorcontrib>Yokota-Ikeda, Naoko</creatorcontrib><creatorcontrib>Minoda, Kunihiro</creatorcontrib><creatorcontrib>Hashiguchi, Hiroshi</creatorcontrib><creatorcontrib>Yoshida, Shuro</creatorcontrib><creatorcontrib>Kuriyama, Takuro</creatorcontrib><creatorcontrib>Yamashita, Kiyoshi</creatorcontrib><creatorcontrib>Miyazaki, Yoshimasa</creatorcontrib><creatorcontrib>Inoue, Sanshiro</creatorcontrib><creatorcontrib>Shimao, Yoshiya</creatorcontrib><creatorcontrib>Kodama, Keiko</creatorcontrib><creatorcontrib>Uezono, Shigehiro</creatorcontrib><creatorcontrib>Ueda, Akira</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>CEN case reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kawano, Noriaki</au><au>Yokota-Ikeda, Naoko</au><au>Minoda, Kunihiro</au><au>Hashiguchi, Hiroshi</au><au>Yoshida, Shuro</au><au>Kuriyama, Takuro</au><au>Yamashita, Kiyoshi</au><au>Miyazaki, Yoshimasa</au><au>Inoue, Sanshiro</au><au>Shimao, Yoshiya</au><au>Kodama, Keiko</au><au>Uezono, Shigehiro</au><au>Ueda, Akira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Successful treatment of bortezomib-refractory multiple myeloma derived from monoclonal gammopathy of undetermined significance with dose-adjusted lenalidomide therapy in a patient with concomitant end-stage renal disease due to diabetic nephropathy requiring haemodialysis</atitle><jtitle>CEN case reports</jtitle><stitle>CEN Case Rep</stitle><addtitle>CEN Case Rep</addtitle><date>2014-05-01</date><risdate>2014</risdate><volume>3</volume><issue>1</issue><spage>24</spage><epage>29</epage><pages>24-29</pages><issn>2192-4449</issn><eissn>2192-4449</eissn><abstract>Malignancy is a fatal complication of end-stage renal disease (ESRD) requiring haemodialysis. However, the successful treatment of haematological malignancies has been rarely reported. We describe the case of a 63-year-old man who presented with IgA-type multiple myeloma (MM; Durie–Salmon stage IIIB) derived from monoclonal gammopathy of undetermined significance concomitant with ESRD due to diabetic nephropathy. First, haemodialysis was initiated before chemotherapy, and bortezomib and dexamethasone were found to be ineffective. Subsequently, 8 courses of dose-adjusted lenalidomide therapy were administered according to the degree of haematological and renal functions. The patient remained in partial remission without disease progression for 21 months. Thus, lenalidomide therapy is effective for bortezomib-refractory MM concomitant with ESRD.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>28509247</pmid><doi>10.1007/s13730-013-0078-x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2192-4449 |
| ispartof | CEN case reports, 2014-05, Vol.3 (1), p.24-29 |
| issn | 2192-4449 2192-4449 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5413672 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Case Report Medicine Medicine & Public Health Nephrology Urology |
| title | Successful treatment of bortezomib-refractory multiple myeloma derived from monoclonal gammopathy of undetermined significance with dose-adjusted lenalidomide therapy in a patient with concomitant end-stage renal disease due to diabetic nephropathy requiring haemodialysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T21%3A39%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Successful%20treatment%20of%20bortezomib-refractory%20multiple%20myeloma%20derived%20from%20monoclonal%20gammopathy%20of%20undetermined%20significance%20with%20dose-adjusted%20lenalidomide%20therapy%20in%20a%20patient%20with%20concomitant%20end-stage%20renal%20disease%20due%20to%20diabetic%20nephropathy%20requiring%20haemodialysis&rft.jtitle=CEN%20case%20reports&rft.au=Kawano,%20Noriaki&rft.date=2014-05-01&rft.volume=3&rft.issue=1&rft.spage=24&rft.epage=29&rft.pages=24-29&rft.issn=2192-4449&rft.eissn=2192-4449&rft_id=info:doi/10.1007/s13730-013-0078-x&rft_dat=%3Cproquest_pubme%3E1899408190%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1899408190&rft_id=info:pmid/28509247&rfr_iscdi=true |